Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients
NCT ID: NCT03036748
Last Updated: 2022-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
14 participants
INTERVENTIONAL
2017-01-01
2021-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
Interventions:◦Dietary Supplement: Standardized salt diet
◦Drug: Amiloride
•Experimental: Kidney transplant recipient with ACR\< 30mg/g (Control) receiving a standardized salt diet (150 mmol NaCl/day) for 5 days, then amiloride tablet 10 mg two times daily (morning and afternoon) for 1 day.
Interventions:◦Dietary Supplement: Standardized salt diet
◦Drug: Amiloride
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TX control
Kidney transplant recipients with urinary albumin/creatinin-ratio \< 30mg/g
Standardized sodium diet
Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.
Tbl amiloride
Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day
TX Proteinuria
Kidney transplant recipients with urinary albumin/creatinin-ratio \> 300mg/g
Standardized sodium diet
Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.
Tbl amiloride
Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standardized sodium diet
Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.
Tbl amiloride
Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* One Group of kidney transplant recipients with ACR \>300mg/g
Exclusion Criteria
* Pregnancy
* Clinically relevant organic or systemic disease including malignancy
* eGFR or creatinin-clearance \< 30ml/min
* hyperkalemia (s-potassium \> 5,0mmol/l)
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Odense University Hospital
OTHER
Region of Southern Denmark
OTHER
University of Southern Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gitte Rye Hinrichs
Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gitte Rye Hinrichs, MD, PHD
Role: PRINCIPAL_INVESTIGATOR
Cardiovascular and Renal research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Odense University Hospital
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Isaksson GL, Hinrichs GR, Andersen H, Bach ML, Weyer K, Zachar R, Henriksen JE, Madsen K, Lund IK, Mollet G, Bistrup C, Birn H, Jensen BL, Palarasah Y. Amiloride Reduces Urokinase/Plasminogen-Driven Intratubular Complement Activation in Glomerular Proteinuria. J Am Soc Nephrol. 2024 Apr 1;35(4):410-425. doi: 10.1681/ASN.0000000000000312. Epub 2024 Jan 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENaC activation
Identifier Type: -
Identifier Source: org_study_id